Oxymetazoline

Registered South African indications:

• Nasal congestion

Contraindications

• Hypersensitivity to the active ingredient or any of its excipients
• Inflammation or lesions of skin around the nostrils/ nasal mucousa 
• Nasal surgery exposing dura mater or trans-sphenoidal hypophysectomy 
• Phaeochromocytoma 
• Coadministration with other sympathomimetic decongestants

Cautions

• Pregnancy
• Breastfeeding
• Hypertension
• Cardiac disease including angina
• Diabetes mellitus
• Hyperthyroidism
• Prostatic hypertrorphy
• Occlusive vascular disease
• Closed angle glaucoma

Forms avail. in SA and covered in this monograph: nas, dro

Nasal congestion

• Nasal (nas, dro): 0.05%. 2-3 drops/2-3 metered actuations/1 unmetered actuation per nostril, 8-12hrly

Use nasal preparation for a maximum of 3 days to prevent rebound rhinitis

Paed. forms avail. in SA and covered in this monograph: nas, dro

Nasal congestion

Younger than 6 years

• Nasal (nas, dro): 0.025%. 2-3 drops/2-3 metered actuations, 8-12hrly

Older than 6 years

• See adult dosage

Use nasal preparation for a maximum of 3 days to prevent rebound rhinitis

Pregnancy

• Caution
• For oxymetazoline no clinical data on exposed pregnancies are available. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development. Caution should be exercised during pregnancy as oxymetazoline may be systemically absorbed

Breastfeeding

• Caution
• It is unknown whether oxymetazoline hydrochloride is excreted into breast milk. The recommended dose should not be exceeded because overdosing can reduce milk production. Caution should be exercised during breastfeeding as oxymetazoline may be systemically absorbed

Renal Impairment

•  No dose adjustment recommended

Hepatic Impairment

•  No dose adjustment recommended

Elderly

• No dose adjustment recommended

Porphyria Information

• Probably not porphyrinogenic (PNP)

Drugs in Sport

•  Permitted - No warnings

Central Nervous System Disorders

• Headaches
• Dizziness
• Insomnia
• Nervousness
• Tremor
• Anxiety

Cardiovascular Disorders

• Palpitations
• Hypertension
• Tachycardia

Respiratory Disorders

• Sneezing
• Dry mouth and throat
• Rebound nasal congestion

Gastrointestinal Disorders

• Nausea

Skin and Subcutaneous Tissue Disorders

• Localised burning 
• Contact dermatitis

• Monoamine oxidase inhibitors 
• Adrenergic neurone-blocking agents 
• Centrally acting antiadrenergic agents
• Antihypertensives
• Appetite suppressants
• Amphetamine-like psychostimulants
• Antiparkinson agents
• Cardiac glycosides
• Ergot alkaloids

None routine

Nose drops 0.025% , Nose Drops 0.05%, Nasal Spray 0.05% - EML (Primary)

Oxymetazoline is an alpha-adrenergic agonist that acts on nasal and ophthalmic vasculature to produce vasoconstriction thus relieving symptoms of congestion.

Nose drops (per ml) 0.25mg

• Drinasal Paediatric 0.025% (Xixia)
• Iliadin Paediatric 0.025% (Merck) originator
• Zadin (Sandoz)

Nose drops (per ml) 0.5mg

• Iliadin Nose Drops 0.05% (Merck) originator
• Zadin (Sandoz)

Nose drops (per ml) 0.1mg

• Iliadin 0.01% (Merck) originator

Nasal spray (per spray) 0.25mg

• Drinasal Paediatric 0.025% (Xixia)
• Iliadin Paediatric 0.025% (Merck) originator
• Oxymist 0,025 (Cipla)
• Zadin (Sandoz)

Nasal spray (per spray) 0.5mg

• Dristan (Pfizer) originator
• Drixine 0.05% Adult (Bayer) originator
• Illiadin Metered 0.05% (Merck) originator
• Nazene Adult (Adcock)
• Oxymist 0,5 (Cipla)
• Oxyspray Moisturising (Zydus)
• Vicks sinex pump (Procter & Gamble)
• Vicks sinex squeeze (Procter & Gamble)
• Zadin metered (Sandoz)

Also available in the following form: Eye drop.